U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07105384) titled 'Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy' on March 27.
Brief Summary: The aim of this clinical trial is to explore the potential of novel 2nd generation tau PET radiotracers as biomarkers in cases suggestive of progressive supranuclear palsy (PSP), an atypical form of parkinsonism.
Study Start Date: Feb. 04
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease
Intervention:
COMBINATION_PRODUCT: Radiotracer
Patients will receive a brain tau radiotracer
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Fundacion Clinic per a la Recerca Biom...